Emyria is a clinical-stage biotech company pioneering psychedelic-assisted therapy for mental health. They are investigating the use of MDMA and psilocybin alongside psychotherapy to treat conditions like PTSD and depression. Their research extends beyond existing drugs, as they develop novel MDMA-like compounds targeting a broader range of neurological disorders, including Parkinson's disease. Emyria's mission is to create effective and scalable solutions, making a significant contribution to global mental healthcare.

Box opened with moth flying out
Emyria has not published yet

Follow this page to get an alert about all news, announcements and livestreams.